Assertio Holdings Earnings Call Transcripts
Fiscal Year 2025
-
ROLVEDON remains the primary growth driver, with 2026 guidance reflecting normalized sales and margin expansion. Indocin faces expected declines from generic competition, while disciplined capital allocation and a robust oncology-focused commercial platform position the company for future growth.
-
Strong Q3 results driven by a Rosedown sales pull forward led to higher revenue and EBITDA, with guidance narrowed for 2025. Rosedown and Synthesan showed growth, while Indocin faced generic pressure. Cash flow will temporarily dip due to sales timing.
-
Q2 2025 saw $28.8M in sales, strong ROLVEDON and SYMPAZAN growth, and improved adjusted EBITDA. Legal settlements, Otrexup exit, and cost actions sharpened focus on core assets, with guidance narrowed and profitability outlook raised.
-
A transformation-focused specialty pharma is prioritizing growth assets Rolvedon and Sympazan, reducing legal exposure, and pursuing M&A to drive future expansion. Financial guidance is maintained, with Rolvedon expected to expand market share and new strategic deals anticipated.
-
Q1 2025 sales were $26M, with gross margin at 70% and adjusted EBITDA at $0.2M. Legal liabilities were largely divested, and guidance for 2025 remains unchanged, with growth expected from ROLVEDON and Sympazan as payer coverage expands.
Fiscal Year 2024
-
2024 marked a stabilization year with Rolvedon surpassing $60M in sales and Indocin declining due to generics. 2025 guidance projects $108–$123M in net sales and $10–$19M adjusted EBITDA, with growth focused on Rolvedon and Sympazan, while legal and market uncertainties persist.
-
Q3 sales declined slightly to $28.7M, with Rolvedon stable at $15M and Indocin down due to generics. Gross margin improved to 74%, net loss narrowed, and cash remained strong. Guidance is unchanged as the company focuses on Rolvedon growth and new asset acquisitions.
-
Leadership is focused on optimizing a small portfolio, with Rolvedon as the main growth driver. Expansion into hospital and 340B markets, plus a completed same-day dosing study, support long-term growth. Cash reserves enable potential acquisitions and creative deal structuring.
-
Q2 2024 saw ROLVEDON drive sequential growth amid Indocin's expected decline, with total sales at $30.7M and adjusted EBITDA at $5M. Cash reserves rose to $88.4M, and 2024 guidance was maintained. ROLVEDON is expected to remain the primary growth driver.
-
Strong Q1 results and a robust cash position support guidance for $110–$125 million in 2024 sales and $20–$30 million in adjusted EBITDA. Rolvedon leads growth, with potential to reach $100 million in sales, while a same-day dosing trial could provide further upside.